Opinion|Videos|April 27, 2023
Clinical Data on Finerenone in Diabetic Kidney Disease
Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.
Advertisement
Advertisement
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Advertisement
Advertisement
Trending on HCPLive
1
The HCPFive: Top News for Healthcare Providers from the Week of 09/13
2
FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
When Innovation Builds Clinical Confidence: Evaluating Treatment Options in Hemophilia A
5